Back to top
more

FibroGen (FGEN)

(Delayed Data from NSDQ)

$1.14 USD

1.14
780,507

+0.01 (0.88%)

Updated May 3, 2024 04:00 PM ET

After-Market: $1.13 -0.01 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?

Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

    What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

    Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.

      Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?

      Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.

        GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?

        GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.

          What's in the Cards for ACADIA (ACAD) this Earnings Season?

          ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.

            Radius Health (RDUS) Q1 Earnings: What's in Store?

            Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3.

              What's in Store for Zoetis (ZTS) Stock This Earnings Season?

              Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.

                What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?

                Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.

                  Is Intercept (ICPT) Poised for a Beat This Earnings Season?

                  Is Intercept (ICPT) Poised for a Beat this Earnings Season?

                    What to Expect from Keryx (KERX) Stock This Earnings Season?

                    Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.

                      What's in the Cards for Merrimack (MACK) in Q1 Earnings?

                      Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations

                        What to Expect from Prothena (PRTA) This Earnings Season?

                        Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.

                          What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?

                          Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.

                            Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%

                            Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares jumped almost 6% on the day.

                              FibroGen (FGEN) Shares March Higher, Can It Continue?

                              FibroGen, Inc. (FGEN) has been on the move lately as the stock has risen by 29.3% in the past four weeks, and it is currently trading well above its 20-Day SMA